activin antagonist peptide Activin receptor IIB competitors - Versanis Activin is a pluripotent growth factor Activin Antagonist Peptides: Targeting Muscle Growth, Fibrosis, and Beyond

Bym338 Activin antagonist peptides represent a class of molecules designed to interfere with the signaling pathways of activins, a group of growth factors crucial for a wide range of physiological processes. By blocking the action of activins, these peptides hold significant therapeutic potential, particularly in areas such as muscle development, the treatment of fibrotic diseases, and metabolic regulationFollistatin, also known as activin-bindings protein, is a protein that in humans is encoded by the FST gene. Follistatin is an autocrine glycoprotein that .... Understanding how activin antagonist peptides function and their diverse applications is key to appreciating their growing importance in biomedical research and drug development.

The core function of activin antagonist peptides lies in their ability to inhibit the binding of activins to their receptors, primarily the activin type II receptors (ActRIIA and ActRIIB). Activins, along with related proteins like myostatin and growth differentiation factor 11 (GDF11), are part of the transforming growth factor-beta (TGF-β) superfamily.Follistatin They exert their effects by binding to ActRII receptors, which then signal downstream to regulate gene expression. Myostatin, for instance, is a potent inhibitor of muscle growth, and its blockade using antagonists can lead to increased muscle mass. Similarly, activins themselves play roles in processes such as cell proliferation, differentiation, and tissue repair, but can also contribute to pathological conditions like fibrosis.

Mechanisms of Action and Key Targets

Activin antagonist peptides can operate through several mechanisms to achieve their inhibitory effects. Some peptides are designed to directly bind to activins, preventing them from interacting with their receptors. Others are engineered to mimic natural inhibitors like follistatin, a protein that effectively sequesters activins, rendering them unable to signal. A prominent strategy involves targeting the activin type II receptors themselves. By acting as a decoy or by binding to the receptor to prevent activin engagement, these peptides effectively shut down the downstream signaling cascade.Follistatin, also known as activin-bindings protein, is a protein that in humans is encoded by the FST gene. Follistatin is an autocrine glycoprotein that ...

A significant area of research focuses on the blockade of myostatin and activin A signaling. Myostatin is a key negative regulator of skeletal muscle mass, and its inhibition has shown promise in treating muscle-wasting conditions.2025年6月2日—The trial demonstrated that approximately 35% of semaglutide-induced weight loss was due to loss of lean mass. Activin A, while involved in beneficial processes like wound healing and immune modulation, can also drive fibrotic responses in various organs, contributing to diseases like idiopathic pulmonary fibrosis (IPF)Myostatin inhibitory peptide 7is a 23 amino acids peptide, which is derived from amino acids 21 to 43 of the mouse myostatin prodomain.. Therefore, activin antagonist peptides that simultaneously neutralize myostatin and activin A offer a dual approach to combatting muscle loss and fibrosis.

Therapeutic Applications and Potential

The therapeutic implications of activin antagonist peptides are broad and continue to expandActivin A (ACVR1B) Blocking Peptide. One of the most explored applications is in muscle enhancement and preservationFollistatin, also known as activin-bindings protein, is a protein that in humans is encoded by the FST gene. Follistatin is an autocrine glycoprotein that .... By inhibiting myostatin and/or activin A, these peptides can promote muscle hypertrophy (growth) and prevent muscle atrophy, which is often associated with aging, disease, or certain medical treatments like those involving glucagon-like peptide-1 receptor agonists (GLP-1RAs).作者：D Gonzalez Trotter·2025·被引用次数：5—GDF8 andactivinA are the key negative regulators of muscle mass in postmenopausal females: a randomized phase I trial · Data availability. Research has indicated that dual blockade of myostatin and activin A can protect against GLP-1-induced muscle loss while simultaneously promoting fat loss, presenting a novel strategy for body composition management作者：AT Kadiombo·2017·被引用次数：22—Activin A has multiple effects on various tissues.Activin A modulates the immune system as an inflammatory cytokineand also influences gonadal steroid ....

Beyond muscle, fibrosis is another major targetGeneration of Novel, Orally Active Selective Macrocyclic .... In conditions like IPF, excessive deposition of extracellular matrix in the lungs, driven in part by activin A signaling, leads to impaired lung function. Activin A inhibitory peptides that target epithelial-mesenchymal transition and fibroblast-myofibroblast transformation are being investigated as potential treatments for such fibrotic diseases作者：D Gonzalez Trotter·2025·被引用次数：5—GDF8 andactivinA are the key negative regulators of muscle mass in postmenopausal females: a randomized phase I trial · Data availability..

Furthermore, activin antagonists are being explored for their role in reproductive health, embryonic development, and immune system modulation, given the pleiotropic effects of activins. The ability of activin A to act as an inflammatory cytokine highlights its involvement in immune responses, suggesting that its antagonists could have applications in modulating inflammation.作者：A Iskenderian·2018·被引用次数：55—Myostatinantagonistsare being developed as therapies for Duchenne muscular dystrophy due to their strong hypertrophic effects on skeletal ...

Challenges and Future Directions

Despite the promising therapeutic potential, the development of activin antagonist peptides faces challenges. Ensuring specificity and avoiding off-target effects is crucial, as activins and related ligands interact with a complex network of signaling pathways. For example, while some antagonists may target all ligands capable of binding the activin type 2B receptor, others are designed for more selective inhibition.Myostatin inhibitory peptide 2 - MedchemExpress.com Developing orally active and bioavailable peptide therapeutics remains a significant hurdle, often requiring advanced formulation strategies or the development of small molecule mimetics2025年3月1日—These findings underscore the therapeutic potential of targetingActivinA with syntheticpeptides, offering a promising avenue for IPF ....

The field is also navigating the complexities of regulatory pathways and clinical trial design.作者：A Iskenderian·2018·被引用次数：55—Myostatinantagonistsare being developed as therapies for Duchenne muscular dystrophy due to their strong hypertrophic effects on skeletal ... Understanding the precise roles of different activin family members and their receptors in various diseases is essential for optimizing therapeutic strategies.作者：SJ Lee·2023·被引用次数：44—ACE-031 is able to target all ligands capable of binding the activin type 2B receptor, while bimagrumab targets both activin type 2 receptors ( ... Emerging research into novel activin receptor antagonists, including engineered follistatin derivatives and specific antibodies, continues to push the boundaries of what is possible.

In conclusion, activin antagonist peptides represent a dynamic area of biomedical research with the potential to address significant unmet medical needs.What are activin receptor antagonists and how do they work? By precisely interfering with activin signaling, these molecules offer targeted approaches to muscle growth, fibrosis treatment, and metabolic regulation, promising innovative therapies for a range of conditionsMyostatin inhibitors target muscle loss prevention to fill gap in GLP-1RA ....